What is tesamorelin doing?

Tesamorelin is a manufactured analogue of growth hormone-releasing hormone, also called growth hormone-releasing factor. It stimulates the pituitary to release growth hormone, which raises IGF-1. That differs from injecting growth hormone itself, but stimulating the body’s own production does not make treatment risk-free. The Egrifta label explains both the mechanism and the need for an intact hypothalamic-pituitary system.

The distinction between kinds of fat is useful here. Visceral fat sits around organs inside the abdomen; subcutaneous fat sits beneath the skin. The main tesamorelin trials measured visceral fat on imaging. Less visceral fat does not necessarily mean a large change on the scale, or that every kind of abdominal fat will shrink.

What did the main HIV trials show?

In the 2007 phase 3 trial, 412 adults with HIV and abdominal fat accumulation were randomized to tesamorelin or placebo for 26 weeks. Visceral fat fell by 15.2% in the tesamorelin group and rose by 5.0% in the placebo group. Triglycerides and some cholesterol measures also improved. Most participants were men, and the results came from a defined HIV-associated body-fat disorder.

Those are meaningful positive findings, with limits. More participants stopped tesamorelin because of adverse events, despite no significant difference in the overall frequency of adverse events. The FDA label summarizes two pivotal studies and shows little average effect on body weight. In the extension phases, people switched to placebo regained visceral fat. The studies do not establish a permanent change after treatment ends or a reduction in heart attacks.

The original trial is published even though its ClinicalTrials.gov record has no posted results. A blank results section in one registry is not evidence that a study never reported its findings.

What about liver fat?

A 2014 randomized trial enrolled 50 adults with HIV and abdominal fat accumulation. After six months, the estimated difference in visceral fat change favored tesamorelin by 42 cm², and liver fat also declined compared with placebo. Fasting glucose rose early in treatment, although the overall six-month glucose comparison was not significant.

A 2019 trial in people with HIV and fatty-liver disease randomized 61 participants, of whom 60 received treatment. At 12 months, the between-group effect on liver fat was a reduction of 4.1 percentage points, corresponding to a 37% relative reduction versus placebo. That figure is a comparison between groups, not a promise that every patient loses 37% of their liver fat.

Fibrosis progressed less often in the tesamorelin group, but existing fibrosis did not improve significantly. The overall liver-disease activity score also did not significantly change. The study was small and not powered to settle uncommon harms. These findings support further liver research; they do not establish reversal of scarring or an FDA-approved fatty-liver indication.

Has it been studied in people without HIV?

Yes. In a 2012 randomized trial, 60 adults without HIV had abdominal obesity and reduced growth hormone secretion. Over 12 months, tesamorelin reduced visceral fat by an estimated 35 cm² more than placebo. Triglycerides, an inflammation marker and carotid artery wall thickness also improved. Weight and subcutaneous abdominal fat did not significantly differ between groups.

This was a selected population, excluding diabetes and established pituitary disease, and only 36 participants completed the full year. Average glucose measures did not worsen, and no serious adverse events were reported, but that small study cannot settle long-term safety. The artery measurement was a risk marker, not evidence of fewer cardiovascular events. It is reasonable to recognize the positive findings without treating them as proof for everyone with abdominal fat.

Why are the cognitive findings mixed?

A 2012 placebo-controlled trial randomized 152 older adults, including 66 with mild cognitive impairment, to tesamorelin or placebo for 20 weeks. The main analysis favored tesamorelin on cognition, with a clearer signal in executive function than memory. Reported adverse events were usually mild but more common with treatment, 68% versus 36%. Daily functioning was not measured, so the practical significance of the test changes remained uncertain.

In contrast, a 2025 study in 73 adults with HIV and neurocognitive impairment found no significant cognitive advantage over standard care after six months, despite a reduction in waist circumference. It was open-label and did not use placebo injections. A 2026 placebo-controlled pilot analyzed 22 adults after ten weeks and found no significant conventional group differences in cognition or the other study measures. Exploratory machine-learning findings in brain imaging do not establish a clinical benefit.

The populations and study designs differ, so one result does not cancel another. Together, they leave an uncertain clinical picture. None establishes that tesamorelin prevents dementia.

What is actually approved?

The U.S. approval is for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not an approval for general weight loss, fatty-liver disease, memory problems or anti-aging. The label also says long-term cardiovascular safety has not been established.

There are distinct Egrifta WR and Egrifta SV formulations. WR is still a daily injection: “weekly reconstitution” means a mixed vial supplies seven daily doses. The formulations differ in strength, preparation, dosing and storage, and are explicitly not substitutable. The older trial formulation is also not an instruction for using a newer product. FDA approval of a named formulation does not extend to every online vial or peptide mixture carrying the name tesamorelin.

What are the important risks?

The prescribing information warns about elevated IGF-1, fluid retention, joint symptoms, carpal tunnel symptoms, injection-site reactions and hypersensitivity. Glucose intolerance or diabetes can develop. In the pivotal studies, HbA1c reached the diabetes threshold of 6.5% in 5% of treated participants versus 1% receiving placebo. Stable average glucose in a smaller trial does not remove that risk.

Active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis and known hypersensitivity are contraindications. A previous malignancy requires careful assessment; the long-term effects of sustained IGF-1 elevation remain unknown. Glucose and IGF-1 monitoring, the person’s history and whether visceral fat is actually responding all matter. The full prescribing information gives the product-specific warnings.

What would make the next conversation useful?

Evidence worth knowing

  • Controlled trials show visceral-fat reduction in HIV-associated lipodystrophy.
  • Smaller studies found liver-fat reduction and benefits in selected adults without HIV.

Questions still open

  • Long-term clinical outcomes, durability after stopping and broader use remain uncertain.
  • Cognitive findings are mixed, and an improved scan does not establish a longer or healthier life.

Ask about the plan

  • Does the diagnosis match the evidence and the product’s approved indication?
  • Which formulation is proposed, what will be monitored, and what would count as enough benefit to continue?

Where research is continuing

The TRIUMPH trial is studying tesamorelin alongside exercise in older adults with HIV and abdominal obesity. The registry was recruiting when checked on November 9, 2026, with a planned enrollment of 100 and no posted results. A trial asking whether physical function improves is not yet evidence that it does.

Approved population

Excess abdominal fat in adults with HIV-associated lipodystrophy.

Liver-fat research

Small randomized HIV studies report less liver fat, with limits on what the biopsy findings establish.

Beyond HIV

A selected obesity trial found visceral-fat and metabolic benefits; routine broader use remains unestablished.

Cognition and function

Cognitive results are mixed. The ongoing exercise trial has not posted results.

Questions people ask

Is tesamorelin approved for ordinary weight loss?

No. Its U.S. indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label specifically excludes weight-loss management. A small trial in adults without HIV did find a visceral-fat benefit, but that does not create a general obesity indication.

Does the liver-fat research mean it treats liver scarring?

The 2019 HIV and fatty-liver trial found less liver fat and less fibrosis progression during treatment. It did not show significant improvement in existing fibrosis. That supports further research, not a promise to reverse scarring or an approved indication for fatty-liver disease.

Is Egrifta WR injected once a week?

No. Egrifta WR is injected daily. Its formulation allows one reconstituted vial to supply seven daily doses. Egrifta WR and Egrifta SV have different preparation, dosing and storage requirements. The Egrifta WR label states that the two formulations are not substitutable.

Does tesamorelin improve memory or prevent dementia?

The findings are mixed. A 2012 trial found a cognitive benefit, mainly in executive function. A 2025 HIV study and a small 2026 pilot did not show significant benefit on their conventional cognitive outcomes. These studies do not establish dementia prevention or a reliable memory treatment.

What to take away

  • Tesamorelin has demonstrated visceral-fat benefits in a specific approved population.
  • Research outside HIV exists, but it does not support every weight-loss or cognitive claim.
  • Formulation, glucose risk, IGF-1 and measured response belong in the clinical discussion.

The evidence

Selected original studies, trial records and official prescribing information. See the Science library for related research.

FDA labelEGRIFTA WR (tesamorelin) prescribing information. Revised March 2025. Approved indication, daily treatment with weekly reconstitution, non-substitutability, clinical studies and warnings. Prescribing information
FDA labelEGRIFTA SV (tesamorelin) prescribing information. Separate formulation with its own preparation, dose and storage instructions. Prescribing information
Phase 3 randomized trialMetabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz and colleagues, 2007. HIV-associated abdominal fat accumulation; 412 randomized participants. PubMed 18057338
Trial registryTH9507 in patients with HIV-associated lipodystrophy. Completed, 412 enrolled. No results posted in this registry record; the original trial was published. NCT00123253
Randomized trialEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. Stanley and colleagues, 2014. Visceral and liver fat in 50 randomized participants with HIV. PubMed 25038357
Randomized trialEffects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Stanley and colleagues, 2019. HIV and non-alcoholic fatty liver disease; 61 randomized, 60 treated. PubMed 31611038
Randomized trialMetabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Makimura and colleagues, 2012. Sixty adults without HIV, with abdominal obesity and reduced GH secretion. PubMed 23015655
Randomized trialEffects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Baker and colleagues, 2012. Cognition in 152 older adults, including 66 with mild cognitive impairment. PubMed 22869065
Randomized open-label trialEffects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. Ellis and colleagues, 2025. Cognition in 73 adults with HIV and abdominal obesity; standard-of-care comparator. PubMed 39813152
Randomized pilot trialThe effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. Stewart and colleagues, 2026. Ten-week cognition and brain-connectivity study; 22 participants analyzed. PubMed 42382101
Trial registryTRIUMPH: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV. Recruiting; planned enrollment 100, no results posted. Record last updated May 19, 2026; checked November 9, 2026. NCT06554717

Sources and U.S. regulatory information checked November 9, 2026.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Approval and clinical use depend on the specific product, indication and jurisdiction. Any treatment decision should be made with a qualified physician. Individual results vary.